ArticleFrontiers in pharmacology2025
Exploring the diagnostic potential of IL1R1 in depression and its association with lipid metabolism.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integration of network pharmacology, molecular docking, and molecular dynamics simulation to elucidate the mechanism of Psychotria rubra in depression treatment.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Depression is a complex mental disorder where oxidative stress and lipid metabolism disorders play crucial roles, yet their connection requires further exploration. This study aims to investigate the roles of oxidative stress and lipid metabolism disorders in depression using bioinformatics methods and Mendelian randomization analysis. Methods: A differential gene expression analysis was performed on the GSE76826 dataset, followed by identification of the intersection with genes related to OS. Subsequently, support vector machine (SVM) and random forest algorithms were employed to determine the optimal division of feature variables. The diagnostic performance was evaluated using a ROC diagnostic model and Diagnostic Nomogram. Furthermore, Mendelian randomization (MR) analysis was conducted to explore the causal relationship between the gene and depression. The expression patterns of key genes in brain tissue were analyzed using the Human eFP Browser database, while their associations with metabolism-related genes were investigated using the STRING database. Finally, DrugnomeAI was utilized to assess the drug development potential of these genes, and small molecule compounds targeting them were identified through dgidb and ChEMBL databases; molecular docking studies were then conducted to evaluate their binding affinity. Results: By conducting a comprehensive analysis of oxidative stress-related genes and depression-related target genes, we have successfully identified 12 overlapping genes. These 12 genes were selected using support vector machine and random forest algorithms. Upon analyzing the diagnostic model, it was revealed that EPAS1 and IL1R1 serve as key biomarkers for OS in depression, with IL1R1 exhibiting the highest diagnostic potential among them. Additionally, MRfen analysis suggests that IL1R1 may play a protective role against depression. Notably, this gene exhibits high expression levels in crucial brain regions such as the olfactory bulb, corpus callosum, and hippocampus. Furthermore, our findings indicate an association between IL1R1 and lipid-related genes PDGFB, PIK3R1, TNFRSFIAA NOD2, and LYN. DrugnomeAI analysis indicated promising medicinal value for ILIRI with BI 639667 demonstrating superior binding affinity among the selected small molecule drugs. Conclusion: This study provides novel insights into the association between OS and dyslipidemia metabolism in depression, offering potential therapeutic targets for future drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.